Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion - part I

被引:160
作者
Verreck, G
Six, K
Van den Mooter, G
Baert, L
Peeters, J
Brewster, ME
机构
[1] Janssen Pharmaceut, Johnson & Johnson Pharmaceut Res & Dev, Pharmaceut Sci, B-2340 Beerse, Belgium
[2] Janssen Pharmaceut, Johnson & Johnson Pharmaceut Res & Dev, Pharmaceut Prod & Dev, B-2340 Beerse, Belgium
[3] Katholieke Univ Leuven, Lab Farmacotechnol & Biofarm, B-300 Louvain, Belgium
关键词
solid dispersion; itraconazole; melt extrusion;
D O I
10.1016/S0378-5173(02)00591-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Solid dispersions containing different ratios of itraconazole and hydroxypropylmethylcellulose (HPMC) were prepared by solvent casting. Based on dose, differential scanning calorimetry and dissolution results, a drug/polymer ratio of 40/60 w/w was selected in order to prepare dispersions by melt extrusion. The melt extrusion process was characterized using a design of experiments (DOE) approach. All parameter settings resulted in the formation of an amorphous solid dispersion whereby HPMC 2910 5 mPa s prevents re-crystallization of the drug during cooling. Dissolution measurements demonstrated that a significantly increased dissolution rate was obtained with the amorphous solid dispersion compared to the physical mixture. The outcome of DOE further indicated that melt extrusion is very robust with regard to the itraconazole/HPMC melt extrudate characteristics. Stability studies demonstrated that the itraconazole/HPMC 40/60 w/w milled melt extrudate formulation is chemically and physically stable for periods in excess of 6 months as indicated by the absence of degradation products or re-crystallization of the drug. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:165 / 174
页数:10
相关论文
共 19 条
[1]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[2]  
BAERT L, 1997, Patent No. 9744014
[3]   Pharmacology of itraconazole [J].
De Beule, K ;
Van Gestel, J .
DRUGS, 2001, 61 (Suppl 1) :27-37
[4]  
Dressman J, 2001, PHARM TECH, V25, P68
[5]   Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms [J].
Dressman, JB ;
Amidon, GL ;
Reppas, C ;
Shah, VP .
PHARMACEUTICAL RESEARCH, 1998, 15 (01) :11-22
[6]  
ERKOBONI D, 2000, Patent No. 0056726
[7]  
GILIS PA, Patent No. 5633015
[8]   ITRACONAZOLE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN SUPERFICIAL AND SYSTEMIC MYCOSES [J].
GRANT, SM ;
CLISSOLD, SP .
DRUGS, 1989, 37 (03) :310-344
[9]  
Grunhagen H.H., 1995, PHARM MANUF PACK SOU, V1, P167
[10]   Itraconazole: an effective oral antifungal for onychomycosis [J].
Jain, S ;
Sehgal, VN .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2001, 40 (01) :1-5